Child's Nervous System

, Volume 29, Issue 12, pp 2301–2305 | Cite as

Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex

  • A. M. Cappellano
  • A. A. Senerchia
  • F. Adolfo
  • P. M. Paiva
  • R. Pinho
  • A. Covic
  • S. Cavalheiro
  • N. Saba
Case Report

Abstract

Purpose

Tuberous sclerosis complex (TSC) is associated with hamartomatous growths including subependymal giant cell astrocytomas (SEGAs). Although, SEGAs are slow-growing glioneuronal tumors, they represent a significant cause of morbidity and mortality due to the risk of sudden death from acute hydrocephalus. Neurosurgical resection has been the mainstay of therapy, since radiotherapy and chemotherapy were proved inefficient in those tumors. Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis.

Methods

We describe the clinical and radiological progression of three pediatric patients with definitive diagnosis of TSC and SEGA, which have been treated with everolimus.

Results

Up to 34 % sustained SEGA decrease was observed in the three cases. All three patients have experienced seizure control and two of them have showed cognitive and behavioral improvement. Everolimus has been well tolerated by all. No severe adverse events have been observed to date.

Conclusion

Everolimus offers significant promise in treating SEGAs. Studies are required to explore optimal therapy duration and management upon discontinuing therapy.

Keywords

Tuberous sclerosis complex Subependymal giant cell astrocytoma mTOR Everolimus 

Notes

Acknowledgments

We are grateful to Novartis Biociências S.A. for providing everolimus throughout the full treatment period for all three patients.

Study funding

This study was supported by Novartis Biociências S.A.

References

  1. 1.
    Orlova KA, Crino PB (2010) The tuberous sclerosis complex. Ann N Y Acad Sci 1184:87–105PubMedCrossRefGoogle Scholar
  2. 2.
    Osborne JP, Fryer A, Webb D (1991) Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 615:125–127PubMedCrossRefGoogle Scholar
  3. 3.
    Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345–1356PubMedCrossRefGoogle Scholar
  4. 4.
    Curatolo P, Bombardieri R (2008) Tuberous sclerosis. Handb Clin Neurol 87:129–151PubMedGoogle Scholar
  5. 5.
    Curatolo P, Porfirio MC, Manzi B, Seri S (2004) Autism in tuberous sclerosis. Eur J Paediatr Neurol 8:327–332PubMedCrossRefGoogle Scholar
  6. 6.
    Curatolo P, D'Argenzio L, Cerminara C, Bombardieri R (2008) Management of epilepsy in tuberous sclerosis complex. Expert Rev Neurother 8:457–467PubMedCrossRefGoogle Scholar
  7. 7.
    Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, Prokop M (2009) Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 16:691–696PubMedCrossRefGoogle Scholar
  8. 8.
    Berhouma M (2010) Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon’s perspective. World J Pediatr 6:103–110PubMedCrossRefGoogle Scholar
  9. 9.
    Moavero R, Pinci M, Bombardieri R, Curatolo P (2011) The management of subependymal giant cell tumors in tuberous sclerosis: a clinician’s perspective. Childs Nerv Syst 27:1203–1210PubMedCrossRefGoogle Scholar
  10. 10.
    Yalon M, Ben-Sira L, Constantini S, Toren A (2011) Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv Syst 27:179–181PubMedCrossRefGoogle Scholar
  11. 11.
    Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498PubMedCrossRefGoogle Scholar
  12. 12.
    Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811PubMedCrossRefGoogle Scholar
  13. 13.
    Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125–132PubMedCrossRefGoogle Scholar
  14. 14.
    Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN (2013) Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80:574–580PubMedCrossRefGoogle Scholar
  15. 15.
    Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461PubMedCrossRefGoogle Scholar
  16. 16.
    Bollo RJ, Kalhorn SP, Carlson C, Haegeli V, Devinsky O, Weiner HL (2008) Epilepsy surgery and tuberous sclerosis complex: special considerations. Neurosurg Focus 25:E13PubMedCrossRefGoogle Scholar
  17. 17.
    Franz DN (2011) Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Rev Anticancer Ther 11:1181–1192PubMedCrossRefGoogle Scholar
  18. 18.
    Jiang T, Jia G, Ma Z, Luo S, Zhang Y (2011) The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. Childs Nerv Syst 27:55–62PubMedCrossRefGoogle Scholar
  19. 19.
    Huang S, Houghton PJ (2001) Mechanisms of resistance to rapamycins. Drug Resist Updat 4:378–391PubMedCrossRefGoogle Scholar
  20. 20.
    Yu J, Parkhitko A, Henske EP (2011) Autophagy: an “Achilles” heel of tumorigenesis in TSC and LAM. Autophagy 7:1400–1401PubMedCrossRefGoogle Scholar
  21. 21.
    Lam C, Bouffet E, Tabori U, Mabbott D, Taylor M, Bartels U (2010) Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatr Blood Cancer 54:476–479PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • A. M. Cappellano
    • 1
  • A. A. Senerchia
    • 1
  • F. Adolfo
    • 1
  • P. M. Paiva
    • 1
  • R. Pinho
    • 1
  • A. Covic
    • 1
  • S. Cavalheiro
    • 1
  • N. Saba
    • 1
  1. 1.Institute of Pediatric Oncology, GRAACCFederal University of São PauloSão PauloBrazil

Personalised recommendations